Editas Medicine (EDIT) shares were up almost 7% in recent trading Monday after the company said that its renizgamglogene autogedtemcel, or reni-cel, therapy continued to be well-tolerated in sickle cell disease patients.
Updated data from the company's clinical trial showed that all 28 subjects with severe sickle cell disease showed a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant, Editas said.
The company also said that 27 of the patients experienced no vaso-occlusive events, that cause pain and other complications, while some patients showed improvements in markers such as hemoglobin levels and fetal hemoglobin.
Editas said it would present the updated clinical data at the American Society of Hematology annual meeting on Monday.
Price: 2.29, Change: +0.15, Percent Change: +6.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。